Long - term survival in a <font color="red">phase_1</font> <font color="red">III_1</font> <font color="red">,_1</font> <font color="red">randomised_1</font> <font color="red">study_1</font> <font color="red">of_1</font> <font color="red">topotecan_1</font> <font color="red">versus_1</font> <font color="red">paclitaxel_1</font> <font color="red">in_1</font> <font color="red">advanced_3</font> <font color="red">epithelial_3</font> <font color="red">ovarian_3</font> <font color="red">carcinoma_3</font> <font color="red">._3</font> 
<br>
<br> BACKGROUND We have continued to monitor the <font color="red">survival_1</font> <font color="red">of_1</font> <font color="red">patients_3</font> <font color="red">randomised_2</font> <font color="red">in_2</font> <font color="red">a_2</font> <font color="red">previously_2</font> <font color="red">reported_2</font> <font color="red">multicentre_2</font> <font color="red">phase_2</font> <font color="red">III_2</font> <font color="red">study_2</font> <font color="red">of_2</font> <font color="red">topotecan_2</font> <font color="red">versus_2</font> <font color="red">paclitaxel_3</font> <font color="red">in_3</font> <font color="red">patients_5</font> <font color="red">with_4</font> <font color="red">advanced_4</font> <font color="red">epithelial_4</font> <font color="red">ovarian_4</font> <font color="red">cancer_4</font> <font color="red">who_4</font> <font color="red">had_4</font> <font color="red">failed_4</font> <font color="red">one_4</font> <font color="red">prior_4</font> <font color="red">platinum_4</font> <font color="red">-_4</font> <font color="red">based_4</font> <font color="red">regimen_4</font> <font color="red">._4</font> 
<br> PATIENTS AND METHODS <font color="red">Patients_6</font> <font color="red">with_6</font> <font color="red">bidimensionally_6</font> <font color="red">measurable_6</font> <font color="red">disease_6</font> <font color="red">were_2</font> <font color="red">randomised_2</font> <font color="red">to_1</font> <font color="red">topotecan_1</font> ( 1.5 mg / m(2)/day for 5 days ) or paclitaxel ( 175 mg / m(2)/day as a 3-h infusion ) every 21 days . <font color="red">Patients_1</font> <font color="red">were_1</font> <font color="red">eligible_1</font> for treatment with the alternate therapy at third line . The European Organisation for Research and Treatment of Cancer Quality of Life ( EORTC <font color="red">QOL)-C30_1</font> <font color="red">questionnaire_1</font> <font color="red">was_1</font> <font color="red">also_1</font> <font color="red">used_1</font> <font color="red">to_1</font> <font color="red">measure_1</font> <font color="red">eight_1</font> <font color="red">symptoms_1</font> <font color="red">at_1</font> <font color="red">baseline_1</font> <font color="red">and_1</font> <font color="red">during_1</font> <font color="red">each_1</font> <font color="red">course_1</font> <font color="red">(_1</font> <font color="red">pain_1</font> <font color="red">,_1</font> <font color="red">anorexia_1</font> <font color="red">,_1</font> <font color="red">diarrhoea_1</font> <font color="red">,_1</font> <font color="red">fatigue_1</font> <font color="red">,_1</font> <font color="red">nausea_1</font> <font color="red">and_1</font> <font color="red">vomiting_1</font> <font color="red">,_1</font> <font color="red">dyspnea_1</font> <font color="red">,_1</font> <font color="red">constipation_1</font> <font color="red">and_1</font> <font color="red">insomnia_1</font> <font color="red">)_1</font> <font color="red">._1</font> 
<br> RESULTS <font color="red">A_3</font> <font color="red">total_3</font> <font color="red">of_3</font> <font color="red">226_7</font> <font color="red">patients_7</font> <font color="red">were_1</font> <font color="red">evaluable_1</font> <font color="red">for_1</font> <font color="red">response_1</font> <font color="red">._1</font> Demographic characteristics were similar in both treatment groups , as were results of the EORTC QOL-30 questionnaire . For the <font color="red">topotecan_1</font> <font color="red">group_1</font> <font color="red">,_1</font> median time to progression was 18.9 weeks ( range < 1 to 92.6 + weeks ; 25% censored ) , and , for paclitaxel , 14.7 weeks ( range < 1 to 137.3 + weeks ; 12.3% censored ) ; P = 0.076 . At 4 years post - randomisation , median survival in the topotecan group was 63.0 weeks ( range < 1 to 238.4 + weeks ; 20.5% censored ) and , for paclitaxel , 53.0 weeks ( range < 1 to 226.3 + weeks ; 12.3% censored ) ; P = 0.44 . 
<br> CONCLUSION Topotecan continues to demonstrate comparable efficacy and survival to paclitaxel with manageable and non - cumulative haematological toxicity . <font color="red">Non_1</font> <font color="red">-_1</font> <font color="red">haematological_1</font> <font color="red">toxicity_1</font> <font color="red">was_1</font> <font color="red">generally_1</font> <font color="red">mild_1</font> <font color="red">for_1</font> <font color="red">both_1</font> <font color="red">groups_1</font> <font color="red">._1</font> The long - term survival rate indicates substantial therapeutic benefit for <font color="red">this_1</font> <font color="red">group_2</font> <font color="red">of_2</font> <font color="red">patients_2</font> <font color="red">receiving_2</font> <font color="red">topotecan_2</font> <font color="red">at_1</font> <font color="red">relapse_2</font> <font color="red">of_2</font> <font color="red">ovarian_2</font> <font color="red">cancer_2</font> <font color="red">._2</font> <font color="red">
<br>
<br>_1</font>